In-depth Proteomic Analysis of Six Types of Exudative Pleural Effusions for Nonsmall Cell Lung Cancer Biomarker Discovery

• DOI: 10.1074/mcp.m114.045914
• Publication Date: 2015-02-01T01:54:51Z
• Authors: Pei-Jun Liu; Chi-De Chen; Chih-Liang Wang; Yi-Cheng Wu; Chia-Wei Hsu; Chien-Wei Lee; Lien-Hung Huang; Jau-Song Yu; Yu-Sun Chang; Chih-Ching Wu; Chia-Jung Yu
• Keywords: Male; Proteomics; 0301 basic medicine; Pleural Cavity; Principal Component Analysis; Lung Neoplasms; Pleural Neoplasms; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Middle Aged; Proto-Oncogene Proteins c-met; Neoplasm Proteins; 3. Good health; Pleural Effusion; 03 medical and health sciences; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Multivariate Analysis; Biomarkers, Tumor; Cluster Analysis; Humans; Female

Pleural effusion (PE), a tumor-proximal body fluid, may be a promising source for biomarker discovery in human cancers. Because a variety of pathological conditions can lead to PE, characterization of the relative PE proteomic profiles from different types of PEs would accelerate discovery of potential PE biomarkers specifically used to diagnose pulmonary disorders. Using quantitative proteomic approaches, we identified 772 nonredundant proteins from six types of exudative PEs, including three malignant PEs (MPE, from lung, breast, and gastric cancers), one lung cancer paramalignant PE, and two benign diseases (tuberculosis and pneumonia). Spectral counting was utilized to semiquantify PE protein levels. Principal component analysis, hierarchical clustering, and Gene Ontology of cellular process analyses revealed differential levels and functional profiling of proteins in each type of PE. We identified 30 candidate proteins with twofold higher levels (q<0.05) in lung cancer MPEs than in the two benign PEs. Three potential markers, MET, DPP4, and PTPRF, were further verified by ELISA using 345 PE samples. The protein levels of these potential biomarkers were significantly higher in lung cancer MPE than in benign diseases or lung cancer paramalignant PE. The area under the receiver-operator characteristic curve for three combined biomarkers in discriminating lung cancer MPE from benign diseases was 0.903. We also observed that the PE protein levels were more clearly discriminated in effusions in which the cytological examination was positive and that they would be useful in rescuing the false negative of cytological examination in diagnosis of nonsmall cell lung cancer-MPE. Western blotting analysis further demonstrated that MET overexpression in lung cancer cells would contribute to the elevation of soluble MET in MPE. Our results collectively demonstrate the utility of label-free quantitative proteomic approaches in establishing differential PE proteomes and provide a new database of proteins that can be used to facilitate identification of pulmonary disorder-related biomarkers.